CLAIM #6223 · Amgen Inc (AMGN) · 2025Q2 earnings call · Aug 5, 2025 · due Dec 14, 2025
“We look forward to the upcoming December 14 PDUFA date for generalized myasthenia gravis, recognizing ever more the significant unmet need for durable, convenient therapies consistently highlighted to us by treating physicians.”
Jay Bradner · EVP R&D
PENDING
graded after results covering Dec 14, 2025 are reported
Verify independently
SEC filings for AMGN ↗ · Claim quote is verbatim from the 2025Q2 earnings call.